AGIO Agios Pharmaceuticals Inc
Agios Pharmaceuticals Inc (AGIO) is expected to report earnings on February 4, 2027, before the market open. The consensus earnings estimate is a loss of $1.19 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -4.8% since its last earnings release on November 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Agios Pharmaceuticals Inc
Agios Pharmaceuticals Inc is engaged in the development of medicines to treat cancer metabolism and inborn errors of metabolism, which are a subset of orphan genetic metabolic diseases.
Sector
Healthcare
Industry
Biotechnology
Held By 1 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.